The Luye Pharma Group has a portfolio of around 30 market-approved products. Twenty-one of these products are approved in China and seven in international markets. Several products are currently in the clinical trial stage for approval by the FDA in the U.S. and by the European authorities.
The Luye Pharma Group was listed on the Hong Kong Stock Exchange in mid-2014. Over the past 22 years, this group of pharmaceutical companies has taken on truly international proportions. In its core operations, it is now a global market leader. It offers innovative products in four of the fastest growing therapeutic areas: oncology, cardiovascular, metabolism, and central nervous system.
The Luye Pharma Group has production facilities and R&D centers in China and Germany as well as offices in the United States, Switzerland, Japan, Malaysia, and Singapore. It has a total of more than 4,000 employees, including 400 -plus engaged in R&D.